PD-1/PD-L1抑制剂在卵巢癌中的研究进展

doi:10.3760/cma.j.cn371439-20200321-00026

摘要/Abstract

摘要：

卵巢癌具有早期诊断困难、易复发、易耐药等特点,其病死率居于妇科肿瘤的首位。现有的手术及放化疗等治疗方法效果欠佳,免疫治疗应运而生。免疫检查点程序性死亡蛋白-1(PD-1)及其配体PD-L1可抑制T细胞增殖、介导肿瘤免疫逃逸。目前,PD-1/PD-L1抑制剂已在多种实体瘤中取得突破性进展,其在卵巢癌临床治疗中也取得初步疗效。

关键词: 卵巢肿瘤, 免疫疗法, PD-1, PD-L1

Abstract:

Ovarian cancer has the characteristics of difficulty in early diagnosis, easy recurrence and resistance, so its mortality rate ranks first in gynecological tumors. Existing treatment methods such as surgery, radiotherapy and chemotherapy are not very effective, thus immunotherapy has emerged. Immune checkpoint programmed death-1 (PD-1) and its ligand PD-L1 can inhibit T cell proliferation and mediate tumor immune escape. At present, PD-1/PD-L1 inhibitors have made breakthrough progress in a variety of solid tumors, and they have achieved initial efficacy in clinical treatment of ovarian cancer.

Key words: Ovarian neoplasms, Immunotherapy, PD-1, PD-L1

薛晨, 赵月, 石光, 唐艳. PD-1/PD-L1抑制剂在卵巢癌中的研究进展[J]. 国际肿瘤学杂志, 2020, 47(5): 312-315.

Xue Chen, Zhao Yue, Shi Guang, Tang Yan. Research progress of PD-1/PD-L1 inhibitors in ovarian cancer[J]. Journal of International Oncology, 2020, 47(5): 312-315.

参考文献 29

[1]	唐南敏, 于占彩. 转化生长因子-β通路与卵巢癌靶向治疗[J]. 国际肿瘤学杂志, 2019,46(9):562-565. DOI: 10.3760/cma.j.issn.1673-422X.2019.09.011.
[2]	Yousefi H, Yuan J, Keshavarz-Fathi M, et al. Immunotherapy of cancers comes of age[J]. Expert Rev Clin Immunol, 2017,13(10):1001-1015. DOI: 10.1080/1744666X.2017.1366315. doi: 10.1080/1744666X.2017.1366315 pmid: 28795649
[3]	Constantinidou A, Alifieris C, Trafalis DT. Targeting programmed cell death-1 (PD-1) and ligand (PD-L1): a new era in cancer active immunotherapy[J]. Pharmacol Ther, 2019,194:84-106. DOI: 10.1016/j.pharmthera.2018.09.008. doi: 10.1016/j.pharmthera.2018.09.008 pmid: 30268773
[4]	唐碧霞, 斯璐, 郭军. 特瑞普利单抗治疗黑色素瘤的适应证分析[J]. 中国肿瘤临床, 2019,46(16):857-860. DOI: 10.3969/j.issn.1000-8179.2019.16.724.
[5]	温霆宇, 刘鹏, 石远凯. 经典型霍奇金淋巴瘤PD-1/PD-L1抑制剂的临床研究进展[J]. 中国慢性病预防与控制, 2019,27(9):715-719. DOI: 10.16386/j.cjpccd.issn.1004-6194.2019.09.020.
[6]	Hawkes EA, Grigg A, Chong G. Programmed cell death-1 inhibition in lymphoma[J]. Lancet Oncol, 2015,16(5):e234-e245. DOI: 10.1016/S1470-2045(15)70103-8. doi: 10.1016/S1470-2045(15)70103-8 pmid: 25943068
[7]	He J, Hu Y, Hu M, et al. Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer[J]. Sci Rep, 2015,5:13110. DOI: 10.1038/srep13110. doi: 10.1038/srep13110 pmid: 26279307
[8]	Jelinek T, Paiva B, Hajek R. Update on PD-1/PD-L1 inhibitors in multiple myeloma[J]. Front Immunol, 2018,9:2431. DOI: 10.3389/fimmu.2018.02431. doi: 10.3389/fimmu.2018.02431 pmid: 30505301
[9]	Shrimali RK, Janik JE, Abu-Eid R, et al. Programmed death-1 & its ligands: promising targets for cancer immunotherapy[J]. Immunotherapy, 2015,7(7):777-792. DOI: 10.2217/imt.15.49. doi: 10.2217/imt.15.49 pmid: 26250412
[10]	Kamimura N, Wolf AM, Iwai Y. Development of cancer immunotherapy targeting the PD-1 pathway[J]. J Nippon Med Sch, 2019,86(1):10-14. DOI: 10.1272/jnms.JNMS.2019_86-2. doi: 10.1272/jnms.JNMS.2019_86-2 pmid: 30918149
[11]	Li Y, Li F, Jiang F, et al. A mini-review for cancer immunotherapy: molecular understanding of PD-1/PD-L1 pathway & translational blockade of immune checkpoints[J]. Int J Mol Sci, 2016,17(7):1151. DOI: 10.3390/ijms17071151. doi: 10.3390/ijms17071151
[12]	Butte MJ, Keir ME, Phamduy TB, et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses[J]. Immunity, 2007,27(1):111-122. DOI: 10.1016/j.immuni.2007.05.016. doi: 10.1016/j.immuni.2007.05.016
[13]	Varga A, Piha-Paul S, Ott PA, et al. Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: analysis of KEYNOTE-028[J]. Gynecol Oncol, 2019,152(2):243-250. DOI: 10.1016/j.ygyno.2018.11.017. doi: 10.1016/j.ygyno.2018.11.017 pmid: 30522700
[14]	Matulonis UA, Shapira-Frommer R, Santin AD, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrentovarian cancer: results from the phase Ⅱ KEYNOTE-100 study[J]. Ann Oncol, 2019,30(7):1080-1087. DOI: 10.1093/annonc/mdz135. doi: 10.1093/annonc/mdz135 pmid: 31046082
[15]	Hamanishi J, Mandai M, Ikeda T, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer[J]. J Clin Oncol, 2015,33(34):4015-4022. DOI: 10.1200/JCO.2015.62.3397. doi: 10.1200/JCO.2015.62.3397 pmid: 26351349
[16]	Liu JF, Gordon M, Veneris J, et al. Safety, clinical activity and biomarker assessments of atezolizumab from a phase Ⅰ study in advanced/recurrent ovarian and uterine cancers[J]. Gynecol Oncol, 2019,154(2):314-322. DOI: 10.1016/j.ygyno.2019.05.021. doi: 10.1016/j.ygyno.2019.05.021 pmid: 31204078
[17]	Moore KN, Pignata S. Trials in progress: IMagyn050/GOG 3015 /ENGOT-OV39. A phase Ⅲ, multicenter, randomized study of atezolizumab versus placebo administered in combination with paclita-xel, carboplatin, and bevacizumab to patients with newly-diagnosed stage Ⅲ or stage Ⅳ ovarian, fallopian tube, or primary peritoneal cancer[J]. Int J Gynecol Cancer, 2019: ijgc-2018-000071. DOI: 10.1136/ijgc-2018-000071.
[18]	Disis ML, Taylor MH, Kelly K, et al. Efficacy and safety of avelu-mab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial[J]. JAMA Oncol, 2019,5(3):393-401. DOI: 10.1001/jamaoncol.2018.6258. doi: 10.1001/jamaoncol.2018.6258 pmid: 30676622
[19]	Pujade-Lauraine E, Fujiwara K, Dychter SS, et al. Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 phase Ⅲ study design[J]. Future Oncol, 2018,14(21):2103-2113. DOI: 10.2217/fon-2018-0070. doi: 10.2217/fon-2018-0070 pmid: 29584456
[20]	Lee JY, Yi JY, Kim HS, et al. An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION[J]. Jpn J Clin Oncol, 2019,49(8):789-792. DOI: 10.1093/jjco/hyz085. doi: 10.1093/jjco/hyz085 pmid: 31671191
[21]	Nivolumab with or without ipilimumab in treating patients with persistent or recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer[EB/OL]. [2020-04-05]. https://www.clinicaltrials.gov/ct2/show/NCT02498600?term=NCT02498600&draw=2& rank=1.
[22]	Durvalumab and tremelimumab in treating participants with recurrent or refractory ovarian, primary peritoneal, or fallopian tube cancer[EB/OL]. [2020-04-05].https://www.clinicaltrials.gov/ct2/show/NCT03026062?term=NCT03026062&draw=2&rank=1.
[23]	Phase 1b/2 Study of avelumab with or without entinostat in patients with advanced epithelial ovarian cancer[EB/OL]. [2020-04-05].https://www.clinicaltrials.gov/ct2/show/nct02915523?term=nct02915523&draw=1&rank=1.
[24]	Phase 2 study of pembrolizumab, DPX-survivac vaccine and cyclophosphamide in advanced ovarian, primary peritoneal or fallopian tube cancer[EB/OL]. [2020-04-05]. https://www.clinicaltrials.gov/ct2/show/NCT03029403?term=NCT03029403&draw=2& rank=1.
[25]	A study of pembrolizumab with standard treatment in patients with recurrent platinum-resistant ovarian cancer (PemCiGem[EB/OL]. [2020-04-05].https://www.clinicaltrials.gov/ct2/show/NCT02608684?term=NCT02608684&draw=2&rank=1.
[26]	Phase Ⅱ: pembrolizumab/carboplatin/taxol in epithelial ovary cancer[EB/OL]. [2020-04-05].https://www.clinicaltrials.gov/ct2/show/NCT02766582?term=NCT02766582&draw=2&rank=1.
[27]	BEACON-ABC in recurrent platinum resistant HGSOC (BEACON)[EB/OL]. [2020-04-05].https://www.clinicaltrials.gov/ct2/show/NCT03363867?4term=NCT03363867&draw=2&rank=1.
[28]	Konstantinopoulos PA, Waggoner S, Vidal GA, et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma[J]. JAMA Oncol, 2019,5(8):1141-1149. DOI: 10.1001/jamaoncol.2019.1048. doi: 10.1001/jamaoncol.2019.1048
[29]	Tymon-Rosario J, Zeybek B, Han C, et al. Synergistic clinical efficacy of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma[J]. Ann Transl Med, 2019,7(Suppl 8):S308. DOI: 10.21037/atm.2019.10.28. doi: 10.21037/atm.2019.10.28 pmid: 32016027